Syphilis Immunoassay Diagnostics Market Size By Product, By Technology, By End-User, By Geographic Scope And Forecast
According to Verified Market Research, The Global Syphilis Immunoassay Diagnostics Market was valued at USD 299.15 Million in 2019 and is projected to reach USD 341.54 Million by 2027, growing at a CAGR of 1.68 % from 2020 to 2027. What is Syphilis Immunoassay Diagnostics? Syphilis is a chronic bacterial disease that spreads around mostly by sexual activity. It can be treated with antibiotics, particularly in the early stage. It is one of the vital sexually transmitted infections (STIs) spread by the Treponema pallidum bacteria, which leads to long-term complications, if not treated early. The disease is mostly diagnosed through clinical findings and serologic testing. The serologic diagnosis of syphilis involves the detection of two types of antibodies; treponemal antibodies and nontreponemal antibodies. The prototype of syphilis testing has been reallocated in many centers to diagnose with a treponemal antibody test, guiding to a nontreponemal test if the treponemal antibody is tested positive. There are different methods used for diagnosing syphilis cases, such as the RPR test, venereal disease research laboratory (VDRL) test, enzyme immunoassay (EIA) test, and few others. The diagnosis of syphilis always depends on a high level of clinical suspicion and routine screening for populations at increased risk. Get | Download Sample Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=39822&utm_source=Free&utm_medium=004
35 views • 3 slides